MALAT1 and Ewing sarcoma: In other cancer research aiming to develop a therapeutic target for the treatment of Ewing sarcoma (EWS), it was found that MALAT1 transcription was dependent on spleen tyrosine kinase (SYK)-mediated signaling, and c-MYC TF promoting SYK’s binding to the MALAT1 promoter, which enhanced the proliferation of EWS [38].